Gene products differentially expressed in cancerous breast cells and their methods of use

• US 20060141455A1
• Filed: 01/08/2003
• Published: 06/29/2006
• Est. Priority Date: 01/08/2002
• Status: Abandoned Application

• Current Assignee: Chiron Corporation (Bayer AG)
• Original Assignee: Chiron Corporation (Bayer AG)
• Inventors: Hansen, Rhonda
• Application Number:
  US10/501,187
• Publication Number:
  US 20060141455A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 16/3015 Breast
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2500/10 involving cells
• CPC Class Codes: G01N 33/57415 of breast

Abstract

The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in breast cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of breast cancer cells. These methods are useful for treating breast cancer.

Claims

1. A method for inhibiting a cancerous phenotype of a cell, said method comprising:

contacting a cancerous mammalian cell with an agent for inhibition of DKFZp5661133 activity.

2. The method of claim 1, wherein said test cell is a breast cell.

3. The method of claims 1-2, wherein said cancerous phenotype is aberrant cellular proliferation relative to a normal cell.

4. The method of claims 1-3, wherein said cancerous phenotype is loss of contact inhibition of cell growth.

5. The method of claims 1-4, wherein said agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

6. The method of claims 1-6, wherein said inhibition is associated with a reduction in a level of DKFZp566I133 protein.

7. The method of claims 1-7, wherein said inhibition is associated with a reduction in a level of DKFZp566I133 RNA.

8. The method of claims 1-8, wherein said inhibition is associated with a reduction in a level of activity of DKFZp566I133 protein.

9. A method for detecting a cancerous cell, said method comprising:

detecting a level of DKFZp566I133 or fragment thereof in a test sample obtained from a cell of a subject,

comparing the level of DKFZp566I133 to a control level of DKFZp5661133,

wherein the presence of a cancerous cell is indicated by detection of said level and comparison to a control level of DKFZp566I133.

10. The method of claim 9, wherein said cancerous cell is a cancerous breast cell.

11. The method of claims 9-10, wherein said gene product is nucleic acid.

12. The method of claims 9-11, wherein said gene product is a polypeptide.

13. The method of claims 9-12, wherein said detecting step uses a polymerase chain reaction.

14. The method of claims 9-13, wherein said detecting step uses hybridization.

15. The method of claims 9-14, wherein said sample is a sample of breast tissue.

16. The method of claims 9-15, wherein said level of said product is indicative of the cancerous state of the cell of the test sample.

17. A method of treating a subject with cancer, said method comprising:

administering to a subject a pharmaceutically effective amount of an agent, wherein said agent modulates the activity of DKFZp566I133.

18. The method of claim 17, wherein said cancer is breast cancer.

19. The method of claims 17-18, wherein said agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

20. A method for assessing the tumor burden of a subject, said method comprising:

detecting a level of DKFZp566I133 in a test sample from a subject,

wherein the level of DKFZp566I133 in the test sample is indicative of the tumor burden in the subject.

21. A method for identifying an agent that modulates a biological activity of a gene product differentially expressed in a cancerous cell as compared to a normal cell, said method comprising:

contacting a candidate agent with a DKFZp566I133; and

detecting modulation of a biological activity of DKFZp566I133 relative to a level of biological activity of DKFZp566I133 in the absence of the candidate agent.

22. The method of claim 21, wherein said cancerous cell and said normal cell are breast cells.

23. The method of claims 21-22, wherein said detecting is by assessing expression of said gene product.

24. The method of claim 23, wherein expression is assessed by detecting a polynucleotide gene product.

25. The method of claims 23-24, wherein expression is assessed by detecting a polypeptide gene product.

26. The method of claims 21-25, wherein said candidate agent is selected from the group consisting of a small molecule, an antibody, an antisense polynucleotide, and an RNAi molecule.

27. The method of claims 21-26, wherein said biological activity is modulation of a cancerous phenotype.

28. The method of claim 27, wherein said cancerous phenotype is abnormal cellular proliferation.

29. The method of claim 27-28, wherein said cancerous phenotype is loss of contact inhibition.

30. An isolated polynucleotide comprising at least 15 contiguous nucleotides of a sequence selected from the group consisting of SEQ ID NO:

1-499.